WO2018164324A1 - 텍토리게닌 7-0-자일로실글루코시드를 포함하는 여성 갱년기 증상 완화용 조성물 - Google Patents
텍토리게닌 7-0-자일로실글루코시드를 포함하는 여성 갱년기 증상 완화용 조성물 Download PDFInfo
- Publication number
- WO2018164324A1 WO2018164324A1 PCT/KR2017/007716 KR2017007716W WO2018164324A1 WO 2018164324 A1 WO2018164324 A1 WO 2018164324A1 KR 2017007716 W KR2017007716 W KR 2017007716W WO 2018164324 A1 WO2018164324 A1 WO 2018164324A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tectorigenin
- composition
- present
- preventing
- xylosylglucoside
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 106
- MCYJIRFKDCXYCX-YUPZTAPUSA-N COc1c(O[C@@H]2O[C@H](CO[C@@H]3OC[C@@H](O)[C@H](O)[C@H]3O)[C@@H](O)[C@H](O)[C@H]2O)cc2occ(-c3ccc(O)cc3)c(=O)c2c1O Chemical compound COc1c(O[C@@H]2O[C@H](CO[C@@H]3OC[C@@H](O)[C@H](O)[C@H]3O)[C@@H](O)[C@H](O)[C@H]2O)cc2occ(-c3ccc(O)cc3)c(=O)c2c1O MCYJIRFKDCXYCX-YUPZTAPUSA-N 0.000 title claims abstract description 30
- MCYJIRFKDCXYCX-UHFFFAOYSA-N tectorigenin 7-O-xylosylglucoside Natural products COc1c(OC2OC(COC3OCC(O)C(O)C3O)C(O)C(O)C2O)cc2occ(-c3ccc(O)cc3)c(=O)c2c1O MCYJIRFKDCXYCX-UHFFFAOYSA-N 0.000 title claims abstract description 30
- 208000024891 symptom Diseases 0.000 title abstract description 25
- 208000011580 syndromic disease Diseases 0.000 title abstract 4
- 208000001132 Osteoporosis Diseases 0.000 claims abstract description 31
- OBBCRPUNCUPUOS-UHFFFAOYSA-N tectorigenin Chemical compound O=C1C2=C(O)C(OC)=C(O)C=C2OC=C1C1=CC=C(O)C=C1 OBBCRPUNCUPUOS-UHFFFAOYSA-N 0.000 claims description 132
- UYLQOGTYNFVQQX-UHFFFAOYSA-N psi-tectorigenin Natural products COC1=C(O)C=C(O)C(C2=O)=C1OC=C2C1=CC=C(O)C=C1 UYLQOGTYNFVQQX-UHFFFAOYSA-N 0.000 claims description 66
- OYUJPVCKGSEYDD-UHFFFAOYSA-N tectorigenin Natural products COc1c(O)cc2OCC(C(=O)c2c1O)c1ccc(O)cc1 OYUJPVCKGSEYDD-UHFFFAOYSA-N 0.000 claims description 66
- FHFSSMDJUNVMNY-UHFFFAOYSA-N tectoridin Natural products COc1c(O)c2C(=O)C(=COc2cc1OC3OC(CO)C(O)C(O)C3O)c4cccc(O)c4 FHFSSMDJUNVMNY-UHFFFAOYSA-N 0.000 claims description 40
- 206010027304 Menopausal symptoms Diseases 0.000 claims description 32
- 206010060800 Hot flush Diseases 0.000 claims description 31
- 208000033830 Hot Flashes Diseases 0.000 claims description 30
- CNOURESJATUGPN-UDEBZQQRSA-N tectoridin Chemical compound C1=C2OC=C(C=3C=CC(O)=CC=3)C(=O)C2=C(O)C(OC)=C1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O CNOURESJATUGPN-UDEBZQQRSA-N 0.000 claims description 26
- 230000035900 sweating Effects 0.000 claims description 24
- 208000008454 Hyperhidrosis Diseases 0.000 claims description 23
- 235000013305 food Nutrition 0.000 claims description 14
- XKNZYDKRYPYTHS-UHFFFAOYSA-N irisolidone-7-O-alpha-D-glucoside Natural products COc1ccc(cc1)C2=COc3cc(OC4OC(CO)C(O)C(O)C4O)c(OC)c(O)c3C2=O XKNZYDKRYPYTHS-UHFFFAOYSA-N 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 11
- 230000002265 prevention Effects 0.000 claims description 10
- 239000002537 cosmetic Substances 0.000 claims description 9
- 230000006872 improvement Effects 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 5
- 230000001166 anti-perspirative effect Effects 0.000 claims description 3
- 239000003213 antiperspirant Substances 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 22
- 238000002657 hormone replacement therapy Methods 0.000 abstract description 3
- 206010016825 Flushing Diseases 0.000 abstract 1
- -1 pack Substances 0.000 description 11
- 238000010521 absorption reaction Methods 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 239000008194 pharmaceutical composition Substances 0.000 description 8
- 239000000843 powder Substances 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 210000000988 bone and bone Anatomy 0.000 description 6
- 239000006071 cream Substances 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 102000015694 estrogen receptors Human genes 0.000 description 5
- 108010038795 estrogen receptors Proteins 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 230000009245 menopause Effects 0.000 description 5
- 230000001457 vasomotor Effects 0.000 description 5
- 241000700159 Rattus Species 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 235000013376 functional food Nutrition 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical group C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 208000017657 Menopausal disease Diseases 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 235000012216 bentonite Nutrition 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 239000000378 calcium silicate Substances 0.000 description 2
- 229910052918 calcium silicate Inorganic materials 0.000 description 2
- 235000012241 calcium silicate Nutrition 0.000 description 2
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 108010049937 collagen type I trimeric cross-linked peptide Proteins 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229930182478 glucoside Natural products 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 238000001794 hormone therapy Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 231100001083 no cytotoxicity Toxicity 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000003075 phytoestrogen Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 2
- 229960003495 thiamine Drugs 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- FGRBYDKOBBBPOI-UHFFFAOYSA-N 10,10-dioxo-2-[4-(N-phenylanilino)phenyl]thioxanthen-9-one Chemical compound O=C1c2ccccc2S(=O)(=O)c2ccc(cc12)-c1ccc(cc1)N(c1ccccc1)c1ccccc1 FGRBYDKOBBBPOI-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- TVEXGJYMHHTVKP-UHFFFAOYSA-N 6-oxabicyclo[3.2.1]oct-3-en-7-one Chemical compound C1C2C(=O)OC1C=CC2 TVEXGJYMHHTVKP-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 208000004483 Dyspareunia Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- LOJFGJZQOKTUBR-XAQOOIOESA-N NC(N)=NCCC[C@@H](C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCC(O)=O)C)CC1=CN=CN1 Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCC(O)=O)C)CC1=CN=CN1 LOJFGJZQOKTUBR-XAQOOIOESA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 206010030247 Oestrogen deficiency Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 206010040799 Skin atrophy Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 206010071018 Urogenital atrophy Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 230000037118 bone strength Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000003792 cranial nerve Anatomy 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 208000020694 gallbladder disease Diseases 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 235000014304 histidine Nutrition 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000013081 microcrystal Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000002346 musculoskeletal system Anatomy 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 238000009806 oophorectomy Methods 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 206010036601 premature menopause Diseases 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 235000013930 proline Nutrition 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 235000004400 serine Nutrition 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 235000002374 tyrosine Nutrition 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000005186 women's health Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/302—Foods, ingredients or supplements having a functional effect on health having a modulating effect on age
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/306—Foods, ingredients or supplements having a functional effect on health having an effect on bone mass, e.g. osteoporosis prevention
Definitions
- the present invention relates to a composition for preventing, improving and / or treating menopausal symptoms in women, and more particularly, to a composition effective for preventing, improving and / or treating hot flashes and / or osteoporosis among menopausal symptoms in women. will be.
- the present invention also relates to a method for preventing, ameliorating and / or treating menopausal symptoms, and more particularly to a method for preventing, ameliorating and / or treating menopausal symptoms in women, in particular hot flashes, and / or osteoporosis.
- Menopause in women is the disruption of menstruation, which occurs when a genetically determined ovary function of about 50 years after birth reaches the end of its life, meaning loss of fertility, and not physiological changes.
- the average life expectancy of Korean women is 81.2 years (2011: Statistics Korea) .Assuming that the average menopausal age of Korean women prescribed by the Korean Academy of Obstetrics and Gynecology is 50, about one-third of their lives are depleted of female hormones. (Pharmaceutical Information Institute, Kim Seong-chul)
- vasomotor symptoms and psychological symptoms such as hot flashes, night sweats, sleep disorders, fatigue, depression, anxiety, concentration disorders, dyspareunia due to memory impairment and urogenital atrophy, loss of skin elasticity due to decreased urine and collagen, and breast Sagging and various diseases such as cardiovascular and musculoskeletal symptoms and dementia are accompanied (Non-Patent Document 1).
- Non-Patent Document 2 Menopausal symptoms vary from person to person, but not only have they been reported to decrease the quality of life of women as they experience more menopausal symptoms, more severely, and longer periods of time. It is more likely to develop into a chronic disease with aging.
- Hormone therapy, drug therapy, exercise therapy, and diet may be used to treat menopausal symptoms, but medically used female hormone therapy may increase the risk of breast cancer, and uterine cancer, thrombovascular disease, and gallbladder disease over long periods of time. May increase the rate of hypertension. Therefore, in recent years, a lot of studies on phytoestrogen (phytoestrogen) that has been reported to function similar to estrogen for the replacement of estrogen therapy and other drug therapy (Non-Patent Document 3).
- menopausal symptoms 89% of women who have had natural menopause experience at least one of the menopausal symptoms, and menopausal symptoms are also reported to be common. Accordingly, the present inventors have developed a material that can effectively alleviate menopausal symptoms and improve hot flashes and osteoporosis due to menopausal symptoms, and a composition for preventing or improving female menopausal symptoms, including tectorigenin 7-O-xyloxyglucoside. Was completed.
- the present invention is to provide a composition for treating, preventing or improving sweating, hot flashes and / or osteoporosis of female menopausal symptoms.
- the present invention seeks to provide a method for treating, preventing or ameliorating sweating, hot flashes and / or osteoporosis among female menopausal symptoms.
- the present invention is to provide a composition that can continue the treatment of women's menopausal symptoms, expression of a palliative effect.
- One embodiment of the present invention is tettorigenin for the manufacture of pharmaceutical preparations for treating, preventing or improving women's menopausal symptoms, sweating, hot flashes and / or osteoporosis
- tectorigen one embodiment of the present invention is a female menopausal symptoms, sweating, hot flashes And / or tectorigenin, tectoridin, tectorigenin 7-O-xylosylglucoside for the preparation of a composition for treating, preventing or improving osteoporosis or The use of mixtures thereof is provided.
- composition may be included in a functional food composition or a pharmaceutical composition.
- the present invention relates to tectorigenin, tectoridin, tectorigenin 7-O-xylosylglucoside or mixtures thereof in female menopausal symptoms, sweating, hot flashes. And / or administered to a patient in need of treatment for osteoporosis.
- the present invention is characterized in that women with menopausal symptoms, sweating, facial tectorigenin (tectorigen), tectoridin, tectorigenin 7-O- xyloyl glucoside (Tectorigenin 7-O-xylosylglucoside) or a mixture thereof
- tectorigen facial tectorigenin
- tectoridin facial tectorigenin
- tectorigenin 7-O- xyloyl glucoside Tectorigenin 7-O-xylosylglucoside
- the present invention provides a composition for preventing, treating or ameliorating female menopausal symptoms, including tectorigenin 7-O-xyloyl glucoside (Tectorigenin 7-O-xylosylglucoside).
- composition of the present invention may further comprise tectorigenin, tectoridin, or mixtures thereof.
- the tectorigenin 7-O-xyloxyglucoside has not yet been known for preventing, treating or ameliorating menopausal symptoms.
- the tectorigenin 7-O-xyloxyglucoside has not been known for preventing, treating or improving hot flashes.
- the present invention provides a composition for treating, preventing or improving hot flashes comprising tectorigenin 7-O-xyloxyglucoside in one embodiment.
- composition may further comprise tectorigenin and tectoridine.
- the present invention provides a composition for treating, preventing or improving osteoporosis, including tetogeninin 7-O-xyloxyglucoside.
- composition may further comprise tectorigenin and tectoridine.
- the present invention provides a composition for treating, preventing or improving an antiperspirant comprising tetorogenin 7-O-xyloxyglucoside.
- composition may further comprise tectorigenin and tectoridine.
- the inventors of the present invention increase the duration in the body when using tectorigenin, tectoridin, and tectorigenin 7-O-xylosylglucoside together, The present invention has been accomplished by confirming that the duration of efficacy can be extended.
- the chemical formula of the tectorigenin 7-O-xyloxyglucoside of the present invention is C 27 H 30 O 15 , the molecular weight is 594.52, it can be represented by the formula (1) below.
- the chemical formula of the tectorigenin of the present invention is C 16 H 12 O 6 , the molecular weight is 300.26, it can be represented by the formula (2) below.
- the chemical formula of tectoridine of the present invention is C 22 H 22 O 11 , the molecular weight is 462.40, and may be represented by the following Chemical Formula 3.
- tectorigenin 7-O-xyloxyglucoside, tectorigenin, and tettoridine three compounds according to the present invention may be chemically synthesized by methods known in the art, or commercially available materials may be used.
- the "menopausal symptoms” are also called “menopausal syndrome” or “menopausal symptoms”.
- compositions of the present invention may have an excellent effect, particularly in the prevention, treatment and / or amelioration of sweating, hot flashes, or osteoporosis during menopausal symptoms.
- the compositions of the present invention may have an excellent effect, especially in the prevention, amelioration and / or treatment of sweating, hot flashes and osteoporosis.
- the compositions of the present invention may have an excellent effect, especially in sweating, hot flashes prevention, amelioration and / or treatment.
- 'flushing' is a representative symptom of vasomotor symptoms known to be experienced by 75% of menopausal women.
- the skin of the neck, neck and chest area suddenly turns red and is accompanied by unpleasant heat and sweating of the whole body.
- Menopausal vasomotor symptoms occur due to the narrowing of the thermoneutral zone in the hypothalamus due to hormonal changes in the menopause, and even if the body temperature rises a little, the heat is felt.
- perspiration is a phenomenon in which sweat is secreted from the sweat glands of the skin, and refers to a symptom of sweating while the heat rises abruptly.
- osteoporosis means a state in which the bone strength is weakened and the fracture is likely to occur, which is caused by genetic factors, early menopause, drugs or smoking. Therefore, it may be 'menopausal osteoporosis' caused by a decrease in hormone production due to menopause of a woman.
- Menopausal osteoporosis refers to osteoporosis symptoms caused by imbalances of osteoblasts involved in bone formation and tissue destruction and absorption due to decreased hormone production in postmenopausal women.
- prevention means any action that inhibits or delays the desired symptom by administering the composition of the present invention.
- treatment means all the actions of improving or disappearing the desired symptom or disease by administering the composition of the present invention.
- the term 'improvement' refers to any behavior in which symptoms are improved or advantageously changed before administration of a desired symptom by administering the composition of the present invention.
- the content of the compound or mixture included in the composition of the present invention may be included in an effective amount.
- the term 'effective amount' refers to an amount of a compound or mixture that can inhibit or delay sweating, hot flashes or osteoporosis, or ameliorate symptoms already present.
- the content of the mixture included in the composition may be included in various weights if it can prevent, improve or treat sweating, hot flashes or osteoporosis.
- the sum of three tettorigenin 7-O-xyloxyglucoside, tectorigenin, tettoridine may be included as 10 ⁇ 500mg based on the daily intake of menopausal women.
- the composition contained in the formulation provided once, the tectorigenin 7-O-xyloxyglucoside, tectorigenin, and tectoridine 10 to 500mg may be included.
- the composition may include tectorigenin, tectoridine, and tectorigenin 7-O-xyloxyglucoside in a weight ratio of 1: 0.5-20: 0.5-20. Preferably it may be included in the weight ratio of 1: 0.8 to 15: 0.8 to 15, more preferably 1: 1.5 to 10: 1.5 to 10.
- the present invention can provide a cosmetic composition, a pharmaceutical composition, a food composition, including a composition comprising a tectorigenin 7-O-xyloxyglucoside.
- the present invention provides a cosmetic composition, pharmaceutical composition, food composition comprising a composition comprising a mixture of tectorigenin, tectoridine, and tectorigenin 7-O-xyloxyglucoside Can be.
- composition may be provided in the form of cosmetics, medicine, food or quasi-drugs.
- the pharmaceutical composition according to the present invention may contain a pharmaceutically effective amount of tectorigenin 7-O-xyloxyglucoside; Or may comprise solely a mixture of tectorigenin, tectoridine, and tectorigenin 7-O-xyloxyglucoside or further comprise one or more pharmaceutically acceptable carriers, excipients or diluents.
- pharmaceutically acceptable is a non-toxic composition that, when physiologically acceptable and administered to humans, does not inhibit the action of the active ingredient and usually does not cause an allergic reaction, such as gastrointestinal disorders, dizziness, or the like.
- Examples of such carriers, excipients or diluents include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose , Polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, mineral oil and the like.
- the pharmaceutical composition may further include fillers, anti-coagulants, lubricants, wetting agents, fragrances, emulsifiers or preservatives.
- the "pharmaceutically effective amount” refers to an amount that exhibits a greater response than the negative control, and preferably an amount sufficient to exhibit the effect of preventing, ameliorating and / or treating a menopausal disorder.
- compositions of the present invention may be formulated using methods known in the art to provide rapid, sustained or delayed release of the active ingredient after administration to a mammal.
- the formulations may be in the form of powders, granules, tablets, emulsions, syrups, aerosols, soft or hard gelatin capsules, sterile injectable solutions, sterile powders.
- Routes of administration of the pharmaceutical compositions of the present invention may be administered orally or parenterally, but not limited thereto.
- Parenteral routes of administration may include various routes, such as, for example, transdermal, nasal, abdominal, muscle, subcutaneous or intravenous.
- compositions of the present invention can be administered in parallel with known compounds that have the effect of preventing, ameliorating and / or treating menopausal disorders.
- the present invention provides a food composition comprising the composition of any one of the above compositions.
- the food composition of the present invention includes processed forms of all natural materials such as foods, functional foods, nutritional supplements, health feeds and food additives.
- Food compositions of this type can be prepared in various forms according to conventional methods known in the art.
- the composition of the present invention may be prepared in the form of tea, juice and drink for drinking, or may be ingested by granulation, encapsulation or powdering.
- the food composition of the present invention may further include other active ingredients and / or additives that may generally be included in the food composition in the art.
- the food composition according to the present invention may include thiamine (vitamin B1), riboflavin, ascorbic acid, niacin, and vitamin B6 as water-soluble vitamins, and myristic acid, palmitic acid, stearic acid, oleic acid, Linoleic acid, and the like, and the weak acid component may include glycolic acid and acetic acid, and as amino acids, including eight essential amino acids of threonine, valine, methionine, isoleucine, leucine, phenylalanine, tryptophan, and lysine, Aspartic acid, serine, glutamic acid, proline, glycine, alanine, cysteine, tyrosine, histidine, arginine and the like.
- the present invention provides a cosmetic composition comprising the composition of any one of the above compositions.
- the components included in the cosmetic composition of the present invention include components conventionally used in cosmetic compositions in addition to the active ingredient of the present invention, and include, for example, conventional auxiliaries such as antioxidants, stabilizers, solubilizers, vitamins, pigments and flavorings, And carriers.
- conventional auxiliaries such as antioxidants, stabilizers, solubilizers, vitamins, pigments and flavorings, And carriers.
- the cosmetics according to the invention can be prepared in any formulations conventionally made in the art.
- it may be formulated as a solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing cleansing, oil, powder foundation, emulsion foundation, wax foundation and spray, It is not limited to this.
- it may be prepared in the form of a flexible lotion, nutrition lotion, nutrition cream, massage cream, essence, eye cream, cleansing cream, cleansing foam, cleansing water, pack, spray or powder.
- a solvent, solubilizer or emulsifier is used as the carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 Fatty acid esters of, 3-butylglycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan.
- liquid carrier diluents such as water, ethanol or propylene glycol
- suspending agents such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, microcrystals Castle cellulose, aluminum metahydroxide, bentonite, agar or tracant and the like can be used.
- the carrier component is aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyltaurate, sarcosinate, fatty acid amide.
- Ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives or ethoxylated glycerol fatty acid esters and the like can be used.
- the formulation of the present invention is a powder or a spray
- lactose, talc, silica, aluminum hydroxide, calcium silicate, or polyamide powder may be used, in particular in the case of a spray, additionally chloro fluorohydrocarbons.
- Propellant such as propane / butane or dimethyl ether.
- the formulation of the present invention is a paste, cream or gel, animal oils, vegetable oils, waxes, paraffins, starches, trachants, cellulose derivatives, polyethylene glycols, silicones, bentonites, silica, talc or zinc oxide may be used as carrier components.
- animal oils, vegetable oils, waxes, paraffins, starches, trachants, cellulose derivatives, polyethylene glycols, silicones, bentonites, silica, talc or zinc oxide may be used as carrier components.
- animal oils vegetable oils, waxes, paraffins, starches, trachants, cellulose derivatives, polyethylene glycols, silicones, bentonites, silica, talc or zinc oxide
- cellulose derivatives polyethylene glycols
- silicones silicones
- bentonites silica, talc or zinc oxide
- composition according to the present invention has a rapid effect on the prevention, improvement and / or treatment of sweating, hot flashes and / or osteoporosis, it is useful for hormone replacement therapy (HRT) used for the prevention or amelioration of conventional menopausal symptoms.
- HRT hormone replacement therapy
- the composition according to the present invention has no cytotoxicity and is low in side effects enough to be used as a food and is safe, and thus, sweating symptoms, hot flashes, It is widely used as a treatment for osteoporosis.
- composition of the present invention including three mixtures of Tectorigenin 7-O-xylosylglucoside, tectorigenin, tectoridin, can increase the duration of efficacy by increasing the duration of the body. Therefore, it is effective in further increasing the time of hot flashes and sweating and reducing bone absorption.
- 1 is a graph showing the effect of improving the vascular motor symptoms of three mixtures of Tectorigenin 7-O-xylosylglucoside, tectorigenin, tectoridin according to an embodiment of the present invention.
- Figure 2 is a graph showing the bone absorption improvement effect of three mixtures of Tectorigenin 7-O-xylosylglucoside, tectorigenin, tectoridin according to an embodiment of the present invention.
- tectorigenin 7-0-xyloxyglucoside (Tectorigenin 7-O-xylosylglucoside) was purchased from Tokiwa, and tectorigenin and tectoridin were purchased from Sigma-Aldrich.
- Eregen response element (ERE) reporter assay was performed to confirm the activity of three estrogen receptors, Tectorigenin 7-O-xylosylglucoside, tectorigenin, and tectoridin. Experimental method was carried out in the same manner as in Example 1, tectorigenin, tectoridin, Tectorigenin 7-O-xylosylglucoside was treated so that the sum of the three species in the ratio of Table 1 to 10ppm. The experimental results are shown in Table 1 based on the measured value of the negative control (1.0).
- Vascular motor symptoms are known to be experienced by 75% of menopausal women. Hot flushes are a common symptom, with a sudden redness of the skin in the face, neck, head, and chest area, accompanied by unpleasant heat. Skin temperature changes can be assessed as indicators to identify changes in vasomotor symptoms. In animal experiments, the skin surface temperature of rat tail can be measured. (Functional Functional Food Functional Evaluation Guide, 'Can Help Menopausal Women's Health', Korea Food & Drug Administration)
- Sprague-Dawley rats from 11 to 12-week-old females underwent sham operation in 10 animals in group 1 and ovariectomy (OVX) in 50 animals in groups 2-6 (n 10).
- the group was orally administered to the rats every week for 4 weeks at 0.01ml / g body weight from one week after the surgery.
- 17 ⁇ -estradiol (E2) was administered as a positive control group, and the test group was administered with a 1: 5: 5 mixture of tectorigenin, tectoridin, and Tectorigenin 7-O-xylosylglucoside.
- E2 17 ⁇ -estradiol
- the test group was administered with a 1: 5: 5 mixture of tectorigenin, tectoridin, and Tectorigenin 7-O-xylosylglucoside.
- the temperature was measured 2 cm from the start of the tail using an infrared thermometer, and the measurement results are shown in FIG. 1.
- the tail temperature of the Tectorigenin 7-O-xylosylglucoside, tectorigenin, tectoridin when administered Tectorigenin 7-O-xylosylglucoside compared to tectorigenin and tectoridine The rise was most suppressed. On the other hand, it was confirmed that the increase in the tail skin temperature was most suppressed in groups 4 and 5, which were administered with three kinds of Tectorigenin 7-O-xylosylglucoside, tectorigenin, and tectoridin.
- CTX C-terminal telopeptide of type I collagen
- MyBioSource Rat C-telopeptide of type I collagen ELISA Kit
- Tectorigenin 7-O-xylosylglucoside compared to tectorigenin and tetoridine Absorption was most suppressed.
- Tectorigenin 7-O-xylosylglucoside compared to tectorigenin and tetoridine Absorption was most suppressed.
- bone absorption was most suppressed in the group 5 administered three species of Tectorigenin 7-O-xylosylglucoside, tectorigenin and tectoridin.
- composition according to the present invention has a rapid effect on the prevention, improvement and / or treatment of sweating, hot flashes and / or osteoporosis, it is useful for hormone replacement therapy (HRT) used for the prevention or amelioration of conventional menopausal symptoms.
- HRT hormone replacement therapy
- the composition according to the present invention has no cytotoxicity and is low in side effects enough to be used as a food and is safe, and thus, sweating symptoms, hot flashes, It can be used as a treatment for osteoporosis.
- composition of the present invention further increases the time for hot flashes and antiperspirants, and is effective in reducing bone absorption.
- composition of the present invention can be used in pharmaceutical, food, cosmetic composition and the like.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Cosmetics (AREA)
Abstract
Description
구분 | 비율 | 에스트로겐 수용체 활성 | ||
tectorigenin | tectoridin | Tectorigenin 7-O-xylosylglucoside | Fold induction | |
1 | 0 | 0 | 1 | 34 |
2 | 1 | 1 | 1 | 66 |
3 | 1 | 0.5 | 0.5 | 54 |
4 | 1 | 0.5 | 5 | 46 |
5 | 1 | 0.5 | 20 | 37 |
6 | 1 | 5 | 0.5 | 68 |
7 | 1 | 5 | 5 | 75 |
8 | 1 | 5 | 20 | 42 |
9 | 1 | 20 | 0.5 | 66 |
10 | 1 | 20 | 5 | 60 |
11 | 1 | 20 | 20 | 51 |
군 | 수술 | 투여 시료 |
1군 | Sham | 식수 |
2군 | OVX | 식수 |
3군 | OVX | 17β-estradiol(E2), 0.5mg/kg/day |
4군 | OVX | T3*, 5mg/kg/day |
5군 | OVX | T3*, 10mg/kg/day |
6군 | OVX | Tectorigenin, 10mg/kg/day |
7군 | OVX | Tectoridin, 10mg/kg/day |
8군 | OVX | Tectorigenin 7-O-xylosylglucoside, 10mg/kg/day |
군 | 1군 | 2군 | 3군 | 4군 | 5군 | 6군 | 7군 | 8군 |
꼬리 피부온도(℃) | 27.5 | 28.8 | 27.4 | 27.9 | 27.5 | 28.6 | 28.7 | 28.0 |
군 | 1군 | 2군 | 3군 | 4군 | 5군 | 6군 | 7군 | 8군 |
CTX (ng/ml) | 42.3 | 78.2 | 52.6 | 60.7 | 49.1 | 71.5 | 70.4 | 58.4 |
Claims (16)
- 텍토리게닌 7-O-자일로실글루코시드(Tectorigenin 7-O-xylosylglucoside)를 포함하는 여성 갱년기 증상 예방 또는 개선용 조성물.
- 제1항에 있어서, 상기 조성물은 텍토리게닌(tectorigenin), 텍토리딘(tectoridin), 또는 이들의 혼합물을 더 포함하는 것을 특징으로 하는 조성물.
- 제1항에 있어서, 상기 여성 갱년기 증상은 안면홍조, 발한, 및 골다공증으로 이루어진 군에서 선택된 어느 하나 이상인 것을 특징으로 하는 조성물.
- 제3항에 있어서, 상기 여성 갱년기 증상은 안면홍조 및 골다공증 중에서 선택된 어느 1 종 이상인 것을 특징으로 하는 조성물.
- 제2항에 있어서, 상기 조성물은 텍토리게닌, 텍토리딘, 및 텍토리게닌 7-O-자일로실글루코시드를 조성물 내에 일일복용량 10 ~ 500mg 으로 포함하는 것을 특징으로 하는 조성물.
- 제1항에 있어서, 상기 조성물은 텍토리게닌, 텍토리딘, 및 텍토리게닌 7-O-자일로실글루코시드를 1 : 0.5~20 : 0.5~20 의 중량비(텍토리게닌:텍토리딘:텍토리게닌 7-O-자일로실글루코시드)로 포함하는 것을 특징으로 하는 조성물.
- 제1항 또는 제2항에 있어서, 상기 조성물은 화장품, 의약품, 식품 또는 의약외품의 형태로 제공되는 것을 특징으로 하는 조성물.
- 텍토리게닌 7-O-자일로실글루코시드를 포함하는 안면홍조 치료, 예방 또는 개선용 조성물.
- 제8항에 있어서, 상기 조성물은 텍토리게닌 및 텍토리딘을 더 포함하는 것을 특징으로 하는 안면홍조 치료, 예방 또는 개선용 조성물.
- 텍토리게닌 7-O-자일로실글루코시드를 포함하는 골다공증 치료, 예방 또는 개선용 조성물.
- 제10항에 있어서, 상기 조성물은 텍토리게닌 및 텍토리딘을 더 포함하는 것을 특징으로 하는 골다공증 치료, 예방 또는 개선용 조성물.
- 텍토리게닌 7-O-자일로실글루코시드를 포함하는 발한 치료, 예방 또는 개선용 조성물.
- 제12항에 있어서, 상기 조성물은 텍토리게닌 및 텍토리딘을 더 포함하는 것을 특징으로 하는 발한 치료, 예방 또는 개선용 조성물.
- 텍토리게닌 7-O-자일로실글루코시드(Tectorigenin 7-O-xylosylglucoside)를 개체에 투여하여 여성 갱년기 증상을 치료, 예방 또는 개선하는 방법.
- 제14항에 있어서, 상기 방법은 텍토리게닌(tectorigenin), 텍토리딘(tectoridin), 또는 이들의 혼합물을 개체에 더 투여하는 것을 특징으로 하는 방법.
- 제14항에 있어서, 상기 여성 갱년기 증상은 안면홍조, 발한, 및 골다공증으로 이루어진 군에서 선택된 어느 하나 이상인 것을 특징으로 하는 방법.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201780087912.9A CN110381954B (zh) | 2017-03-07 | 2017-07-18 | 包含鸢尾黄素-7-o-木糖葡萄糖苷的女性更年期症状缓和用组合物 |
JP2018518647A JP7384511B2 (ja) | 2017-03-07 | 2017-07-18 | テクトリゲニン-7-0-キシロシルグルコシドを含む女性更年期症状緩和用組成物 |
US16/491,780 US11090324B2 (en) | 2017-03-07 | 2017-07-18 | Composition, for remedying female climacteric syndrome symptoms, comprising tectorigenin 7-O-Xylosylglucoside |
JP2022016457A JP7337435B2 (ja) | 2017-03-07 | 2022-02-04 | テクトリゲニン-7-0-キシロシルグルコシドを含む女性更年期症状緩和用組成物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2017-0028999 | 2017-03-07 | ||
KR1020170028999A KR101965849B1 (ko) | 2017-03-07 | 2017-03-07 | 텍토리게닌 7-0-자일로실글루코시드를 포함하는 여성 갱년기 증상 완화용 조성물 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018164324A1 true WO2018164324A1 (ko) | 2018-09-13 |
Family
ID=63448649
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2017/007716 WO2018164324A1 (ko) | 2017-03-07 | 2017-07-18 | 텍토리게닌 7-0-자일로실글루코시드를 포함하는 여성 갱년기 증상 완화용 조성물 |
Country Status (5)
Country | Link |
---|---|
US (1) | US11090324B2 (ko) |
JP (2) | JP7384511B2 (ko) |
KR (1) | KR101965849B1 (ko) |
CN (1) | CN110381954B (ko) |
WO (1) | WO2018164324A1 (ko) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102178967B1 (ko) * | 2018-10-02 | 2020-11-13 | 주식회사 엘지생활건강 | 갈화 발효 추출물을 포함하는 갱년기 증상의 예방 또는 치료용 조성물 |
KR102324869B1 (ko) * | 2018-10-02 | 2021-11-09 | 주식회사 엘지생활건강 | 분갈 추출물 또는 이로부터 유래된 화합물을 포함하는 피부 개선용 조성물 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140234271A1 (en) * | 2008-09-30 | 2014-08-21 | The Hospital For Sick Children | Compositions for proliferation of cells and related methods |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19812204A1 (de) * | 1998-03-19 | 1999-11-04 | Plantamed Arzneimittel Gmbh | Verwendung von Extrakten aus Cimicifuga racemosa und Belamcanda sinensis als estrogenartiges organselektives Arzneimittel ohne uterotrope Wirkung |
JP2005037278A (ja) * | 2003-07-16 | 2005-02-10 | Matsushita Electric Ind Co Ltd | 健康管理システム |
JP5027502B2 (ja) * | 2004-03-04 | 2012-09-19 | 学校法人近畿大学 | 骨粗鬆症予防または治療剤 |
JP2006206556A (ja) | 2005-01-31 | 2006-08-10 | Ota Isan:Kk | 脳記憶機能低下症状回復剤及びその調製方法 |
CN100381435C (zh) * | 2005-03-24 | 2008-04-16 | 深圳海王药业有限公司 | 射干总黄酮提取物及其制备方法和其在药物制备中的应用 |
KR100740184B1 (ko) | 2006-03-02 | 2007-07-18 | 한국과학기술연구원 | 텍토리딘 또는 그 비배당체를 포함하는 항암용 조성물 |
JP2009126853A (ja) | 2007-11-27 | 2009-06-11 | Tsujido Kagaku Kk | 治療剤 |
JP5768230B2 (ja) * | 2009-04-27 | 2015-08-26 | 学校法人東京女子医科大学 | エストロゲン様作用剤 |
CN101797265A (zh) * | 2010-04-09 | 2010-08-11 | 中国人民解放军第二军医大学 | 射干总异黄酮或异黄酮类化合物在制备防治妇女病的药物或食品中的应用 |
JP5842640B2 (ja) | 2012-01-31 | 2016-01-13 | 株式会社東洋新薬 | ホスホジエステラーゼ3阻害剤 |
CN102631363A (zh) | 2012-04-11 | 2012-08-15 | 李超生 | 鸢尾苷在制备防治骨质疏松症的药物中的应用 |
KR101964841B1 (ko) * | 2017-03-07 | 2019-08-07 | 주식회사 엘지생활건강 | 여성 갱년기 증상 개선용 조성물 |
-
2017
- 2017-03-07 KR KR1020170028999A patent/KR101965849B1/ko active IP Right Grant
- 2017-07-18 WO PCT/KR2017/007716 patent/WO2018164324A1/ko active Application Filing
- 2017-07-18 JP JP2018518647A patent/JP7384511B2/ja active Active
- 2017-07-18 US US16/491,780 patent/US11090324B2/en active Active
- 2017-07-18 CN CN201780087912.9A patent/CN110381954B/zh active Active
-
2022
- 2022-02-04 JP JP2022016457A patent/JP7337435B2/ja active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140234271A1 (en) * | 2008-09-30 | 2014-08-21 | The Hospital For Sick Children | Compositions for proliferation of cells and related methods |
Non-Patent Citations (4)
Title |
---|
KAMIYA, T.: "Evaluation of the estrogenic activity of Pueraria (Kudzu) flower extract and its major isoflavones using ER-binding and uterotrophic bioassays", PHARMACOLOGY & PHARMACY, 2013, pages 255 - 260, XP055605999 * |
LU , J.: "Simultaneous determination of isoflavones, saponins and flavones in Flos Puerariae by ultra performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry", CHEMICAL AND PHARMACEUTICAL BULLETIN, vol. 61, no. 9, 2013, pages 941 - 951, XP055606010 * |
TANAKA, T. ET AL.: "Kudzu (Pueraria lobata) vine ethanol extracts improve ovariectomy-induced bone loss in female mice", JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, vol. 59, 2011, pages 13230 - 13237, XP055119458, DOI: doi:10.1021/jf2031617 * |
YAMAZAKI, T.: "The protective effect of a Puerariae flos extract (thomsonide) against ethanol-induced gastric lesions in rats", PHARMACOLOGY & PHARMACY, 2016, pages 208 - 215, XP055606000 * |
Also Published As
Publication number | Publication date |
---|---|
KR101965849B1 (ko) | 2019-04-04 |
JP7384511B2 (ja) | 2023-11-21 |
US20200030350A1 (en) | 2020-01-30 |
US11090324B2 (en) | 2021-08-17 |
CN110381954B (zh) | 2023-08-08 |
JP2022051835A (ja) | 2022-04-01 |
JP2020509990A (ja) | 2020-04-02 |
JP7337435B2 (ja) | 2023-09-04 |
KR20180102403A (ko) | 2018-09-17 |
CN110381954A (zh) | 2019-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2018164325A1 (ko) | 여성 갱년기 증상 개선용 조성물 | |
US20100105766A1 (en) | Composition for inhibition or prevention of bone density reduction | |
WO2015002393A1 (ko) | 감귤 미성숙과 추출물, 또는 시네프린 또는 이의 염을 유효성분으로 포함하는 염증성 피부질환 치료 또는 예방용 조성물 | |
JP7337435B2 (ja) | テクトリゲニン-7-0-キシロシルグルコシドを含む女性更年期症状緩和用組成物 | |
WO2010123221A2 (ko) | 글리세올린을 유효성분으로 함유하는 갱년기 증상의 예방 및 개선용 조성물 | |
WO2012091492A2 (en) | Herbal extract, pharmaceutical composition including the same and health functional food including the same | |
EP2985037B1 (en) | A pharmaceutical composition comprising palmitoylethanolamid and cytidine-diphosphocholine | |
JPH0529206B2 (ko) | ||
WO2018208107A1 (ko) | 플로로글루시놀을 유효성분으로 하는 수면 장애 개선, 예방 또는 치료용 조성물, 또는 gaba-a 수용체 벤조다이아제핀 결합 위치 효능제의 내성 억제 또는 부작용 경감용 조성물 | |
WO2014007549A2 (ko) | 에스-알릴-엘-시스테인을 유효성분으로 포함하는 대장염 예방 또는 치료용 조성물 및 이를 포함하는 의약제제 | |
WO2018174424A1 (ko) | 능이버섯 추출물을 유효성분으로 함유하는 부인과 질환의 예방 또는 치료용 약학적 조성물 | |
KR102125740B1 (ko) | 텍토리게닌 7-0-자일로실글루코시드를 포함하는 여성 갱년기 증상 완화용 조성물 | |
KR20190034180A (ko) | 여성 갱년기 증상 개선용 조성물 | |
WO2019031655A1 (ko) | 티몰을 유효성분으로 함유하는 피부 주름 또는 아토피성 피부염의 예방 또는 치료용 조성물 | |
WO2014069836A1 (ko) | 폴리코사놀을 유효성분으로 하는 히스타민 수용체 길항제 조성물 | |
Hardt et al. | Suppression of lactation with lisuride | |
WO2010128788A2 (ko) | 캡사이신 또는 캡사이신 유사 화합물을 유효성분으로 함유하는 항비만용 피부 외용제 조성물 | |
WO2018030838A1 (ko) | 락토바실러스 인테스티날리스를 포함하는 갱년기 예방 또는 치료용 조성물 | |
WO2021261870A1 (ko) | 6'-하이드록시 저스티시딘-b(6'-hydroxy justicidin b)를 포함하는 알레르기성 질환의 예방, 개선 또는 치료용 조성물 | |
WO2022220425A1 (ko) | 인간 모유두 세포와 주변 세포들의 염증개선과 5α-환원효소의 발현억제를 통한 탈모완화 또는 치료용 약제학적 조성물 | |
WO2019117501A1 (en) | Composition and method for treating, relieving or preventing muscle cramps, containing choline alfoscerate as active ingredient | |
WO2015060677A1 (ko) | 유제놀을 유효성분으로 함유하는 아토피성 피부염의 예방 또는 치료용 조성물 | |
WO2021242044A1 (ko) | 히비스커스, 로즈마리, 및 포도씨 추출물을 유효성분으로 포함하는 퇴행성 뇌질환의 예방 또는 치료 조성물 | |
JPH01279818A (ja) | 白髪黒化剤 | |
WO2014069837A1 (ko) | 감마오리자놀을 유효성분으로 하는 히스타민 수용체 길항제 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref document number: 2018518647 Country of ref document: JP Kind code of ref document: A |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17899542 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205N DATED 03.12.2019) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 17899542 Country of ref document: EP Kind code of ref document: A1 |